Resource Library
The Resource Library is a compendium of consent forms, risk management recommendations, sample documents, articles, and other risk management materials to promote ophthalmic patient safety and reduce liability. Contact riskmanagement@omic.com with questions.
Found
21
resources.
Apr 21, 2026
| Consent Form
...Letterhead] Informed Consent for Avastin™ (bevacizumab) You have [Condition], and your doctor, [Name, MD/DO], is recommending Avastin™ (bevacizumab) . What is [Condition]? · [State the condition and how it impacts the patient.] About Avastin™ (bevacizumab) Ophthalmologists (eye surgeons) treat some types of eye problems with a medication called Avastin. Avastin...
Apr 21, 2026
| Consent Form
...FDA, issued a warning about AVASTIN. Here is more information about the warning. Tests on animals show that anti-VEGF drugs like AVASTIN may not be safe for the fetus. The FDA does not know if AVASTIN causes birth defects in humans. This drug should only be used during pregnancy if...
Feb 21, 2023
| Recommendation
...needs, and leaves this decision up to the physician’s judgment. Ophthalmologists use the FDA-approved medications just discussed to treat other eye conditions. All such use is off-label. Ophthalmologists use Avastin (bevacizumab), which has not been approved for intravitreal use or for eye conditions. All ophthalmic use of Avastin is off-label....
Mar 10, 2022
| Recommendation
...vasculosa lentis. Some infants have disease that persists despite laser. Other means of arresting ROP are thus needed. Adult patients with retinal conditions due at least in part to VEGF have been successfully treated with intravitreal injections of anti-VEGF agents such as AvastinTM (bevacizumab), MacugenTM (pegaptanib), LucentisTM (ranibizumab), and EyleaTM...
Apr 1, 2022
| Recommendation
...weeks between examinations, depending upon the findings. b. Infants at high risk for ROP may need more frequent examinations. c. Infants treated with an anti-VEGF medication (i.e., Avastin or Lucentis) need to be monitored until at least 65 weeks postmenstrual age (PMA). 5. The ophthalmologist writes an order for the...
Apr 22, 2026
| Consent Form
...changed the safety labeling for intravenous Avastin, adding a section on embryo-fetal toxicity. In that warning, the FDA instructs physicians to “advise females of reproductive potential to use effective contraception during treatment with and for 6 months after the last dose of Avastin.” It is not clear whether intravenous Avastin...
Apr 22, 2026
| Consent Form
...the last dose of Avastin.” It is not clear whether intravenous Avastin causes harm to the human fetus. The FDA warning did not address intrav itreal Avastin, as this use is off - label. Nor did it address intravitreal Eylea. To reduce the potential liability for ophthalmologists using Eylea, we...
Apr 22, 2026
| Consent Form
...on embryo-fetal toxicity. In that warning, the FDA instructs physicians to “advise females of reproductive potential to use effective contraception during treatment with and for 6 months after the last dose of Avastin.” It is not clear whether intravenous Avastin causes harm to the human fetus. The FDA warning did...
Apr 9, 2026
| Consent Form
...medication during the surgery. Scarring can block the channel and develop weeks or months after surgery. Mitomycin-C (MMC), 5-Fluorouracil (5FU), and Avastin (bevacizumab) are the most commonly used anti-scarring medications. MMC is approved by the Food and Drug Administration (FDA) for use in eye surgery. 5FU and Avastin were originally...
Apr 22, 2026
| Consent Form
...the channel. Mitomycin-C (MMC), 5-Fluorouracil (5FU), and Avastin (bevacizumab) are the most commonly used anti-scarring medications. MMC is approved by the Food and Drug Administration (FDA) for use in eye surgery. 5FU and Avastin were originally approved by the FDA for cancer treatment. However, physicians can use FDA-approved drugs for...
Apr 8, 2026
| Consent Form
...restore the flow of fluid through the channel. Mitomycin-C (MMC), 5-Fluorouracil (5FU), and Avastin (bevacizumab) are the most commonly used anti-scarring medications. MMC is approved by the Food and Drug Administration (FDA) for use in eye surgery. 5FU and Avastin were originally approved by the FDA for cancer treatment. However,...
Feb 13, 2020
| Consent Form
...ophthalmologist may recommend more anti-scarring medication or surgery to fix the bleb. Mitomycin-C (MMC), 5-Fluorouracil (5FU), and Avastin (bevacizumab) are the most commonly used anti-scarring medications. MMC is approved by the Food and Drug Administration (FDA) for use in eye surgery. 5FU and Avastin were originally approved by the FDA...
Apr 9, 2026
| Consent Form
...5-Fluorouracil (5FU), and Avastin (bevacizumab) are the most commonly used anti-scarring medications. MMC is approved by the Food and Drug Administration (FDA) for use in eye surgery. 5FU and Avastin were originally approved by the FDA for cancer treatment. However, physicians can use FDA-approved drugs for other purposes (this is...
Apr 9, 2026
| Consent Form
...recommend an injection of more anti-scarring medication or a surgery to fix the bleb so fluid flows again. Mitomycin-C (MMC), 5-Fluorouracil (5FU), and Avastin (bevacizumab) are the most commonly used anti-scarring medications. MMC is approved by the Food and Drug Administration (FDA) for use in eye surgery. 5FU and Avastin...
Apr 21, 2026
| Consent Form
...6 months after the last dose of Avastin.” It is not clear whether intravenous Avastin causes harm to the human fetus. The FDA warning did not address intravitreal Avastin, as this use is off-label. To reduce the potential liability for ophthalmologists using BEOVU, we feel it is prudent to address...
Mar 9, 2023
| Consent Form
...an alternative to laser surgery, ophthalmologists can inject anti-VEGF medication into the baby’s eye to treat ROP. This is called an intravitreal injection. There are many anti-VEGF medications but the ones which are used to treat ROP include Avastin (bevacizumab), Eylea (aflibercept), and Lucentis (ranibizumab). The ophthalmologist will talk to...
Apr 1, 2022
| Recommendation
...high risk for ROP may need more frequent examinations. c. Infants treated with an anti-VEGF medication (i.e., Avastin or Lucentis) need to be monitored until at least 65 weeks postmenstrual age (PMA). 5. The ophthalmologist writes an order for the next exam indicating the interval and approximate date (e.g., next...
Apr 1, 2022
| Recommendation
...[Table 3. Follow-up exams]. a. Current guidelines indicate a range of 1 to 3 weeks between examinations, depending upon the findings. b. Infants at high risk for ROP may need more frequent examinations. c. Infants treated with an anti-VEGF medication (i.e., Avastin or Lucentis) need to be monitored until at...
Apr 24, 2026
| Consent Form
...surgeons use an anti-VEGF drug called AvastinTM (bevacizumab) to treat AMD and refractory macular edema; this use of AvastinTM is off-label. Eye surgeons also use triamcinolone acetonide, a long-acting cortisone-like drug (KenalogTM, TriesenceTM, or TrivarisTM) to treat eye conditions like yours. Your doctor will discuss with you the benefits and...
Jun 14, 2023
| Bulletin
By Michael C. Tigani, MD Chair, OMIC Risk Management Committee
Recently OMIC Risk Management has received a number of inquiries regarding the use of biosimilar medications for ophthalmic care. We would like to clarify our position on this topic. 1. Bevacizumab (Avastin®) biosimilars There is limited intraocular experience with bevacizumab biosimilars because studies leading to their FDA approval were for...
Jan 1, 2023
| Recommendation
...anti-VEGF medication (i.e., Avastin or Lucentis) need to be monitored until at least 65 weeks postmenstrual age (PMA). 5. The ophthalmologist writes an order for the next exam indicating the interval and approximate date (e.g., next eye exam in two weeks around 9/25/22) and: a. Notifies the ROPCs of the...